At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
Immulinadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Identification of Surrogate Blood and/or Urine Biomarker for Immulina TM in Normal Humans
In Brief
A Phase 3 clinical trial evaluating Immulina for Adherence, Patient. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a pilot study for identifying plasma and/or urine-derived adherence/surrogate biomarker candidates for verifying Immulina™ ingestion by human volunteers (collected before and after consumption of Immulina™, a natural dietary supplement).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdherence, Patient
CountriesUnited States
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartAug 2023
Primary CompletionOct 2023
TodayJul 2026
First PostedSep 27, 2022
Enrollment StartAug 9, 2023
Primary CompletionOct 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.8 years ago
Interventions
Immulinadrug
Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.